NDATOPICALSYSTEM
Approved
Sep 2025
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
20
Data completeness
4/8 — Partial
BONDLIDO (lidocaine) by PharmaIN is amide-type local anesthetic and is suggested to stabilize neuronal membranes by inhibiting the ionic fluxes required for the initiation and conduction of impulses. First approved in 2025.
Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BONDLIDO is a topical lidocaine system approved in September 2025 for localized anesthetic use. It works as an amide-type local anesthetic by stabilizing neuronal membranes and inhibiting ionic fluxes required for impulse initiation and conduction. This is a well-established pharmacological class with broad clinical application.
LOE Approaching2.0 years to LOE
Product is rapidly approaching loss of exclusivity with only 2 years of patent protection remaining, signaling a contracted commercial team and focus on defensive market maintenance rather than growth investment.
Mechanism of Action
amide-type local anesthetic and is suggested to stabilize neuronal membranes by inhibiting the ionic fluxes required for the initiation and conduction of impulses.
Pharmacologic Class:
Amide Local Anesthetic
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Localized Injection of Lidocaine Via the Middle Meningeal Artery for Headache Treatment
Started Sep 2026
80 enrolled
Refractory MigraineHeadache
Study to Assess Adverse Events and How Effective NOA LIFT is Compared to JUVÉDERM VOLIFT With Lidocaine for the Correction of Nasolabial Folds in Adults
Started Aug 2026
288 enrolled
Nasolabial Folds
Study to Evaluate the Safety of Retreatment With Restylane® Lyft With Lidocaine for Augmentation of the Chin Region
Started Jun 2026
100 enrolled
Chin Augmentation
Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias
Started Feb 2026
20 enrolled
Leg Veins
Lidocaine for LESS Postoperative Shoulder Pain Alleviation
Started Dec 2025
100 enrolled
CystectomyMyomectomy
Worked on BONDLIDO at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.